Skip to main content
main-content

Pulmonary arterial hypertension

Pulmonary arterial hypertension

16-12-2015 | Pulmonary hypertension | News | Article

Right atrial function could be prognostic in PAH

Right atrial function is impaired in patients with pulmonary arterial hypertension and may indicate right ventricular overload and failure, research suggests.

15-12-2015 | Pulmonary hypertension | News | Article

Early promise for pulmonary artery denervation in PAH patients

Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.

15-12-2015 | Pulmonary hypertension | News | Article

RV glucose metabolism changes associated with RV function

The rate of myocardium glucose utilisation in the right ventricle correlates with its function and could be used to monitor treatment effects in patients with pulmonary arterial hypertension, findings indicate.

16-11-2015 | Pulmonary hypertension | News | Article

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension.

11-11-2015 | Pulmonary hypertension | News | Article

Patient-related outcome shows strong link to survival in PAH

Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.

11-11-2015 | Pulmonary hypertension | News | Article

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.

06-10-2015 | Pulmonary hypertension | News | Article

Support for upfront combination therapy in scleroderma-associated PAH

Upfront therapy with ambrisentan and tadalafil may help patients with scleroderma-associated pulmonary arterial hypertension, research suggests.

05-10-2015 | Pulmonary hypertension | News | Article

Algorithm reduces PAH screening costs in systemic sclerosis patients

The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation.

01-10-2015 | Pulmonary hypertension | News | Article

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

The 6-minute walk distance of patients with systemic sclerosis-associated pulmonary arterial hypertension is not a suitable marker for tracking treatment-related haemodynamic changes, say researchers.

11-09-2015 | Pulmonary hypertension | News | Article

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.

09-09-2015 | Pulmonary hypertension | News | Article

Upfront combination therapy fulfils AMBITION in PAH patients

Upfront treatment with the combination of ambrisentan and tadalafil improves outcomes in patients with pulmonary arterial hypertension more than either treatment as monotherapy, shows a randomised trial.

10-08-2015 | Pulmonary hypertension | News | Article

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.

10-08-2015 | Pulmonary hypertension | News | Article

Low GLSRV heralds adverse outcomes in PAH patients

Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.

04-08-2015 | Pulmonary hypertension | News | Article

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows.

09-07-2015 | Pulmonary hypertension | News | Article

Stress Doppler echocardiography ‘reliable’ for early PAH detection in systemic sclerosis

Researchers recommend performing echocardiography at rest and during exercise to screen for pulmonary arterial hypertension in patients with systemic sclerosis.

09-07-2015 | Pulmonary hypertension | News | Article

Oral PAH treatments stave off clinical decline

Oral treatments for pulmonary arterial hypertension reduce patients’ risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis.

03-07-2015 | Pulmonary hypertension | News | Article

Prognosis still gloomy for idiopathic PAH

Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.

18-06-2015 | Pulmonary hypertension | News | Article

Right ventricular dyssynchrony may be prognostic in PAH

Researchers report that right ventricular dyssynchrony may be a useful prognostic factor in patients with pulmonary arterial hypertension, improving the predictive accuracy of established risk factors.

18-06-2015 | Pulmonary hypertension | News | Article

Immunosuppression may improve PAH outcomes in SLE patients

Patients with pulmonary arterial hypertension arising from systemic lupus erythematosus may benefit from combined immunosuppressive and vasodilator therapy, a small study suggests.

17-06-2015 | Pulmonary hypertension | News | Article

PAH diagnosis delayed for adult congenital heart disease patients

Pulmonary arterial hypertension is often not diagnosed in adult patients with congenital heart disease until 6 years or more after their symptoms first appear, research shows.